Related Experiment Video
Updated: Jun 7, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Anti-GD2 Strategy in the Treatment of Neuroblastoma
Abstract:
The prognosis for advanced neuroblastoma remains poor with high risk of recurrence after consolidation. Therapies based on monoclonal antibodies that specifically target disialoganglioside GD2 on tumor cells are improving treatment results for high-risk neuroblastoma. This article reviews the use of anti-GD2 antibodies either as monotherapy or as part of a larger and more complex treatment approach for advanced neuroblastoma. We review how anti-GD2 antibodies can be combined with other treatments or strategies to enhance their clinical effects. Tumor resistance and other problems that decrease the efficacy of anti-GD2 antibodies are discussed. Future developments in the area of anti-GD2 immunotherapies for neuroblastoma are also addressed.
Insights
Monoclonal antibodies targeting disialoganglioside GD2 improve outcomes for high-risk neuroblastoma. This review covers anti-GD2 antibody therapies, combinations, resistance, and future directions in neuroblastoma immunotherapy.
Area of Science:
- Pediatric Oncology
- Immunotherapy
- Cancer Biology
Background:
- Advanced neuroblastoma has a poor prognosis and high recurrence rates.
- Disialoganglioside GD2 is a tumor-associated antigen expressed on neuroblastoma cells.
Purpose of the Study:
- To review the current use of anti-disialoganglioside GD2 (anti-GD2) antibodies in treating advanced neuroblastoma.
- To explore the combination of anti-GD2 antibodies with other therapeutic strategies.
- To discuss challenges such as tumor resistance and future advancements in anti-GD2 immunotherapy.
Main Methods:
- Literature review of studies on anti-GD2 antibody therapy for neuroblastoma.
- Analysis of clinical trial data and research findings.
- Examination of mechanisms of action and resistance.
Main Results:
- Anti-GD2 antibodies are enhancing treatment outcomes for high-risk neuroblastoma.
- Combination therapies involving anti-GD2 antibodies show potential for improved efficacy.
- Tumor resistance and other factors can limit the effectiveness of anti-GD2 antibodies.
Conclusions:
- Anti-GD2 antibody immunotherapy represents a significant advancement in treating advanced neuroblastoma.
- Further research into optimizing combination strategies and overcoming resistance is crucial.
- Future developments hold promise for further improving survival rates in neuroblastoma patients.
